Pfizer's Undervalued Stock Offers a Safe Haven Amid Market Volatility

Pfizer is trading near multi-year lows, with a forward P/E ratio of 8.6x, significantly lower than the average in the pharmaceutical sector. The company has faced challenges with COVID-19 revenue decline, pipeline failures, and activist campaigns. However, with the exit of activist investors and a reset of financial guidance, the storm appears to have passed. Pfizer offers a solid dividend yield of approximately 6.9% and a low bar for success, making it an attractive value investment.